Ultragenyx Pharma (RARE) Misses Q4 EPS by 2c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($2.16), $0.02 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $103.35 million versus the consensus estimate of $101.94 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
• Virax Biolabs announces 1-for-25 reverse stock split on Nasdaq